Treatment of vasculitic leg ulcers in connective tissue disease with iloprost
Leg ulcers are a recognised manifestation of cutaneous vasculitis in connective tissue diseases (CTDs) including rheumatoid arthritis (RA). Iloprost a stable prostacyclin analogue has been successfully used to treat Raynaud's phenomenon and digital ulcers associated with CTD's. Our aim was...
Gespeichert in:
| Veröffentlicht in: | Clinical rheumatology 1995-03, Vol.14 (2), p.187-190 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 190 |
|---|---|
| container_issue | 2 |
| container_start_page | 187 |
| container_title | Clinical rheumatology |
| container_volume | 14 |
| creator | Veale, D J Muir, A H Morley, K D Belch, J J |
| description | Leg ulcers are a recognised manifestation of cutaneous vasculitis in connective tissue diseases (CTDs) including rheumatoid arthritis (RA). Iloprost a stable prostacyclin analogue has been successfully used to treat Raynaud's phenomenon and digital ulcers associated with CTD's. Our aim was to assess iloprost in the treatment of vasculitic leg ulcers in CTD. In this paper we describe eight cases of vasculitic leg ulceration in association with RA and CTD, treated with intravenous iloprost. The iloprost was administered for 6-8 hours daily and continued for 21-28 days. Immunosuppressive therapy was required in three patients with severe necrotising vasculitis (RAnv). Complete ulcer healing was achieved in four patients within 6 weeks of commencing therapy while rapid improvement occurred in the other four patients. This suggests that iloprost may be useful as an adjunct to therapy for vasculitic leg ulcers. A double-blind placebo controlled study of iloprost therapy for RA leg ulcers is under way. |
| doi_str_mv | 10.1007/BF02214941 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77343638</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77343638</sourcerecordid><originalsourceid>FETCH-LOGICAL-c282t-5c025d328f8dfb17ae8475d13af61c4eed1ea794b0cf9857e04b42f22a65dcab3</originalsourceid><addsrcrecordid>eNpFkD1PwzAYhC0EKqWwsCN5YkAK-CuxPUJFAamIpcyR47wGIycpsVPEvyeoEUy3PLo7PQidU3JNCZE3dyvCGBVa0AM0p4KLTGuhD9GcSEkyTrU6RicxfhBCmNJ0hmYyFyRnxRw9b3owqYE24c7hnYl2CD55iwO84SFY6CP2LbZd24JNfgc4-RgHwLWPYCLgL5_esQ_dtu9iOkVHzoQIZ1Mu0OvqfrN8zNYvD0_L23VmmWIpyy1hec2Zcqp2FZUGlJB5TblxBbUCoKZgpBYVsU6rXAIRlWCOMVPktTUVX6DLfe-4-jlATGXjo4UQTAvdEEspueAFVyN4tQfteC_24Mpt7xvTf5eUlL_uyn93I3wxtQ5VA_UfOsniPx24ahw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77343638</pqid></control><display><type>article</type><title>Treatment of vasculitic leg ulcers in connective tissue disease with iloprost</title><source>MEDLINE</source><source>Springer Online Journals Complete</source><creator>Veale, D J ; Muir, A H ; Morley, K D ; Belch, J J</creator><creatorcontrib>Veale, D J ; Muir, A H ; Morley, K D ; Belch, J J</creatorcontrib><description>Leg ulcers are a recognised manifestation of cutaneous vasculitis in connective tissue diseases (CTDs) including rheumatoid arthritis (RA). Iloprost a stable prostacyclin analogue has been successfully used to treat Raynaud's phenomenon and digital ulcers associated with CTD's. Our aim was to assess iloprost in the treatment of vasculitic leg ulcers in CTD. In this paper we describe eight cases of vasculitic leg ulceration in association with RA and CTD, treated with intravenous iloprost. The iloprost was administered for 6-8 hours daily and continued for 21-28 days. Immunosuppressive therapy was required in three patients with severe necrotising vasculitis (RAnv). Complete ulcer healing was achieved in four patients within 6 weeks of commencing therapy while rapid improvement occurred in the other four patients. This suggests that iloprost may be useful as an adjunct to therapy for vasculitic leg ulcers. A double-blind placebo controlled study of iloprost therapy for RA leg ulcers is under way.</description><identifier>ISSN: 0770-3198</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/BF02214941</identifier><identifier>PMID: 7540526</identifier><language>eng</language><publisher>Germany</publisher><subject>Aged ; Aged, 80 and over ; Arthritis, Rheumatoid - complications ; Arthritis, Rheumatoid - physiopathology ; Connective Tissue Diseases - complications ; Connective Tissue Diseases - physiopathology ; Drug Administration Schedule ; Female ; Humans ; Iloprost - administration & dosage ; Iloprost - therapeutic use ; Immunosuppressive Agents - therapeutic use ; Infusions, Intravenous ; Leg Ulcer - drug therapy ; Leg Ulcer - etiology ; Male ; Middle Aged ; Treatment Outcome ; Vasculitis - drug therapy ; Vasculitis - etiology</subject><ispartof>Clinical rheumatology, 1995-03, Vol.14 (2), p.187-190</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c282t-5c025d328f8dfb17ae8475d13af61c4eed1ea794b0cf9857e04b42f22a65dcab3</citedby><cites>FETCH-LOGICAL-c282t-5c025d328f8dfb17ae8475d13af61c4eed1ea794b0cf9857e04b42f22a65dcab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7540526$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Veale, D J</creatorcontrib><creatorcontrib>Muir, A H</creatorcontrib><creatorcontrib>Morley, K D</creatorcontrib><creatorcontrib>Belch, J J</creatorcontrib><title>Treatment of vasculitic leg ulcers in connective tissue disease with iloprost</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><description>Leg ulcers are a recognised manifestation of cutaneous vasculitis in connective tissue diseases (CTDs) including rheumatoid arthritis (RA). Iloprost a stable prostacyclin analogue has been successfully used to treat Raynaud's phenomenon and digital ulcers associated with CTD's. Our aim was to assess iloprost in the treatment of vasculitic leg ulcers in CTD. In this paper we describe eight cases of vasculitic leg ulceration in association with RA and CTD, treated with intravenous iloprost. The iloprost was administered for 6-8 hours daily and continued for 21-28 days. Immunosuppressive therapy was required in three patients with severe necrotising vasculitis (RAnv). Complete ulcer healing was achieved in four patients within 6 weeks of commencing therapy while rapid improvement occurred in the other four patients. This suggests that iloprost may be useful as an adjunct to therapy for vasculitic leg ulcers. A double-blind placebo controlled study of iloprost therapy for RA leg ulcers is under way.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Arthritis, Rheumatoid - complications</subject><subject>Arthritis, Rheumatoid - physiopathology</subject><subject>Connective Tissue Diseases - complications</subject><subject>Connective Tissue Diseases - physiopathology</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Humans</subject><subject>Iloprost - administration & dosage</subject><subject>Iloprost - therapeutic use</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Infusions, Intravenous</subject><subject>Leg Ulcer - drug therapy</subject><subject>Leg Ulcer - etiology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Treatment Outcome</subject><subject>Vasculitis - drug therapy</subject><subject>Vasculitis - etiology</subject><issn>0770-3198</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkD1PwzAYhC0EKqWwsCN5YkAK-CuxPUJFAamIpcyR47wGIycpsVPEvyeoEUy3PLo7PQidU3JNCZE3dyvCGBVa0AM0p4KLTGuhD9GcSEkyTrU6RicxfhBCmNJ0hmYyFyRnxRw9b3owqYE24c7hnYl2CD55iwO84SFY6CP2LbZd24JNfgc4-RgHwLWPYCLgL5_esQ_dtu9iOkVHzoQIZ1Mu0OvqfrN8zNYvD0_L23VmmWIpyy1hec2Zcqp2FZUGlJB5TblxBbUCoKZgpBYVsU6rXAIRlWCOMVPktTUVX6DLfe-4-jlATGXjo4UQTAvdEEspueAFVyN4tQfteC_24Mpt7xvTf5eUlL_uyn93I3wxtQ5VA_UfOsniPx24ahw</recordid><startdate>199503</startdate><enddate>199503</enddate><creator>Veale, D J</creator><creator>Muir, A H</creator><creator>Morley, K D</creator><creator>Belch, J J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199503</creationdate><title>Treatment of vasculitic leg ulcers in connective tissue disease with iloprost</title><author>Veale, D J ; Muir, A H ; Morley, K D ; Belch, J J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c282t-5c025d328f8dfb17ae8475d13af61c4eed1ea794b0cf9857e04b42f22a65dcab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Arthritis, Rheumatoid - complications</topic><topic>Arthritis, Rheumatoid - physiopathology</topic><topic>Connective Tissue Diseases - complications</topic><topic>Connective Tissue Diseases - physiopathology</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Humans</topic><topic>Iloprost - administration & dosage</topic><topic>Iloprost - therapeutic use</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Infusions, Intravenous</topic><topic>Leg Ulcer - drug therapy</topic><topic>Leg Ulcer - etiology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Treatment Outcome</topic><topic>Vasculitis - drug therapy</topic><topic>Vasculitis - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Veale, D J</creatorcontrib><creatorcontrib>Muir, A H</creatorcontrib><creatorcontrib>Morley, K D</creatorcontrib><creatorcontrib>Belch, J J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Veale, D J</au><au>Muir, A H</au><au>Morley, K D</au><au>Belch, J J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of vasculitic leg ulcers in connective tissue disease with iloprost</atitle><jtitle>Clinical rheumatology</jtitle><addtitle>Clin Rheumatol</addtitle><date>1995-03</date><risdate>1995</risdate><volume>14</volume><issue>2</issue><spage>187</spage><epage>190</epage><pages>187-190</pages><issn>0770-3198</issn><eissn>1434-9949</eissn><abstract>Leg ulcers are a recognised manifestation of cutaneous vasculitis in connective tissue diseases (CTDs) including rheumatoid arthritis (RA). Iloprost a stable prostacyclin analogue has been successfully used to treat Raynaud's phenomenon and digital ulcers associated with CTD's. Our aim was to assess iloprost in the treatment of vasculitic leg ulcers in CTD. In this paper we describe eight cases of vasculitic leg ulceration in association with RA and CTD, treated with intravenous iloprost. The iloprost was administered for 6-8 hours daily and continued for 21-28 days. Immunosuppressive therapy was required in three patients with severe necrotising vasculitis (RAnv). Complete ulcer healing was achieved in four patients within 6 weeks of commencing therapy while rapid improvement occurred in the other four patients. This suggests that iloprost may be useful as an adjunct to therapy for vasculitic leg ulcers. A double-blind placebo controlled study of iloprost therapy for RA leg ulcers is under way.</abstract><cop>Germany</cop><pmid>7540526</pmid><doi>10.1007/BF02214941</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0770-3198 |
| ispartof | Clinical rheumatology, 1995-03, Vol.14 (2), p.187-190 |
| issn | 0770-3198 1434-9949 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77343638 |
| source | MEDLINE; Springer Online Journals Complete |
| subjects | Aged Aged, 80 and over Arthritis, Rheumatoid - complications Arthritis, Rheumatoid - physiopathology Connective Tissue Diseases - complications Connective Tissue Diseases - physiopathology Drug Administration Schedule Female Humans Iloprost - administration & dosage Iloprost - therapeutic use Immunosuppressive Agents - therapeutic use Infusions, Intravenous Leg Ulcer - drug therapy Leg Ulcer - etiology Male Middle Aged Treatment Outcome Vasculitis - drug therapy Vasculitis - etiology |
| title | Treatment of vasculitic leg ulcers in connective tissue disease with iloprost |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T04%3A36%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20vasculitic%20leg%20ulcers%20in%20connective%20tissue%20disease%20with%20iloprost&rft.jtitle=Clinical%20rheumatology&rft.au=Veale,%20D%20J&rft.date=1995-03&rft.volume=14&rft.issue=2&rft.spage=187&rft.epage=190&rft.pages=187-190&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/BF02214941&rft_dat=%3Cproquest_cross%3E77343638%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77343638&rft_id=info:pmid/7540526&rfr_iscdi=true |